You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Blinatumomab

Showing 1 - 25 of 101
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Immune Reconstitution After Allo-HSCT and Blinatumomab

Not yet recruiting
  • Leukemia, Lymphoid
  • blinatumomab
  • (no location specified)
Oct 3, 2023

Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

Recruiting
  • Leukemia, Lymphoid
  • blinatumomab
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Oct 27, 2023

Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

Not yet recruiting
  • Leukemia, Lymphoid
  • blinatumomab
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Oct 3, 2023

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Jul 1, 2023

Next-generation Sequencing in Pediatric B-ALL Children Patients

Not yet recruiting
  • Acute Lymphoblastic Leukemia, Pediatric
  • Blinatumomab
  • (no location specified)
Apr 19, 2023

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • Blinatumomab
  • (no location specified)
Sep 25, 2023

Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Blinatumomab
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Frankfurt, Germany
    Department of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023

Acute Lymphoblastic Leukemia Trial in Houston (Blinatumomab, Hematopoietic Cell Transplantation)

Completed
Has Results
  • Acute Lymphoblastic Leukemia
  • Blinatumomab
  • Hematopoietic Cell Transplantation
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 30, 2022

B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • Blinatumomab
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022

Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome-Positive
  • Blinatumomab
  • +3 more
  • New York, New York
  • +1 more
Nov 10, 2022

Leukemia Trial in Houston (Cyclophosphamide, Vincristine, Blinatumomab)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Dec 23, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab, Conventional therapy)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Blinatumomab
  • Conventional therapy
  • Suzhou, Jiangsu, China
    The first affiliated hospital of Soochow University
Sep 26, 2022

Hematopoietic/Lymphoid Cancer, Richter's Transformation Trial in Houston (Blinatumomab, Dexamethasone)

Completed
  • Hematopoietic/Lymphoid Cancer
  • Richter's Transformation
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 3, 2022

B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Blinatumomab
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Apr 4, 2022

Prior Blinatumomab on Subsequent CD19 CAR Outcomes and

Active, not recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoblastic Leukemia, Acute, Childhood
    • Bethesda, Maryland
      National Cancer Institute (NCI)
    Aug 13, 2022

    Pediatric ALL, B Cell, Minimal Residual Disease Trial in Seoul (Blinatumomab for Injection)

    Recruiting
    • Pediatric ALL, B Cell
    • Minimal Residual Disease
    • Blinatumomab for Injection
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Feb 20, 2022

    Diffuse Large B Cell Lymphoma Trial in Saint Louis (Blinatumomab, Autologous stem cell transplant, Carmustine)

    Active, not recruiting
    • Diffuse Large B Cell Lymphoma
    • Blinatumomab
    • +6 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    May 4, 2022

    Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

    Recruiting
    • Mixed Phenotype Acute Leukemia (MPAL)
    • Measurable Residual Disease (MRD)
    • BLINCYTO (Blinatumomab)
    • Baltimore, Maryland
      Greenebaum Cancer Center at University of Maryland Medical Cente
    Apr 18, 2022

    B-Cell Acute Lymphoblastic Leukemia, Adult Trial in La Jolla, Orange, San Francisco (blinatumomab, pembrolizumab)

    Terminated
    • B-Cell Acute Lymphoblastic Leukemia, Adult
    • La Jolla, California
    • +2 more
    Apr 26, 2022

    B-Precursor ALL Trial in Germany (Blinatumomab)

    Recruiting
    • B-Precursor ALL
    • Blinatumomab
    • Frankfurt (Main), Hessen, Germany
    • +20 more
    Aug 16, 2022

    Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed Trial in Czechia (Blinatumomab)

    Active, not recruiting
    • Lymphoblastic Leukemia, Acute, Adult
    • +2 more
    • Blinatumomab
    • Brno, Czechia
    • +4 more
    Aug 3, 2022

    Lymphoblastic Leukemia Trial in Palo Alto (Dexamethasone, Mitoxantrone, PEG asparaginase)

    Not yet recruiting
    • Lymphoblastic Leukemia
    • Palo Alto, California
      Stanford University
    Apr 27, 2023

    Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia Trial in Japan (Blinatumomab)

    Completed
    Has Results
    • Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
    • Blinatumomab
    • Nagoya-shi, Aichi, Japan
    • +15 more
    Dec 8, 2022